Initial management of lower urinary tract symptoms and bladder outlet obstruction
| Autor: | Mark J. Speakman, Amerdip S. Birring |
|---|---|
| Rok vydání: | 2015 |
| Předmět: |
medicine.medical_specialty
Combination therapy Urinary retention business.industry General Medicine medicine.disease Surgery Bladder outlet obstruction Drug treatment Quality of life Lower urinary tract symptoms Internal medicine medicine Metabolic syndrome medicine.symptom Mirabegron business medicine.drug |
| Zdroj: | Medicine. 43:431-434 |
| ISSN: | 1357-3039 |
| DOI: | 10.1016/j.mpmed.2015.05.006 |
| Popis: | Lower urinary tract symptoms (LUTS) affect more than 60% of men and women aged over 40. Symptoms may be classed as storage, voiding or post-micturition and have a variety of systemic, neurological, drug-related or urological causes. There is growing evidence that metabolic syndrome is linked to LUTS. Initial evaluation of LUTS should follow a structured system, with symptom scores and frequency/volume charts. Several features have been identified as risk factors for progression of LUTS and stratification using these factors can aid in planning management. For example, older age and a high-normal concentration of prostate-specific antigen may suggest a higher risk of progression to acute urinary retention. Many patients with LUTS will require no treatment. For those who do, the initial approach should be conservative, with lifestyle changes; this can be followed where necessary by drug treatment using selective α-adrenoceptor blockers, 5-α reductase inhibitors, antimuscarinics, mirabegron, or a combination of these. Phosphodiesterase-5 inhibitors can also improve symptom scores and quality of life, and may become part of the routine management of LUTS. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect